Literature DB >> 15145981

The VLDL receptor plays a major role in chylomicron metabolism by enhancing LPL-mediated triglyceride hydrolysis.

Jeltje R Goudriaan1, Sonia M S Espirito Santo, Peter J Voshol, Bas Teusink, Ko Willems van Dijk, Bart J M van Vlijmen, Johannes A Romijn, Louis M Havekes, Patrick C N Rensen.   

Abstract

The VLDL receptor (VLDLr) is involved in tissue delivery of VLDL-triglyceride (TG)-derived FFA by facilitating the expression of lipoprotein lipase (LPL). However, vldlr-/- mice do not show altered plasma lipoprotein levels, despite reduced LPL expression. Because LPL activity is crucial in postprandial lipid metabolism, we investigated whether the VLDLr plays a role in chylomicron clearance. Fed plasma TG levels of vldlr-/- mice were 2.5-fold increased compared with those of vldlr+/+ littermates (1.20 +/- 0.37 mM vs. 0.47 +/- 0.18 mM; P < 0.001). Strikingly, an intragastric fat load led to a 9-fold increased postprandial TG response in vldlr-/- compared with vldlr+/+ mice (226 +/- 188 mM/h vs. 25 +/- 11 mM/h; P < 0.05). Accordingly, the plasma clearance of [3H]TG-labeled protein-free chylomicron-mimicking emulsion particles was delayed in vldlr-/- compared with vldlr+/+ mice (half-life of 12.0 +/- 2.6 min vs. 5.5 +/- 0.9 min; P < 0.05), with a 60% decreased uptake of label into adipose tissue (P < 0.05). VLDLr deficiency did not affect the plasma half-life and adipose tissue uptake of albumin-complexed [14C]FFA, indicating that the VLDLr facilitates postprandial LPL-mediated TG hydrolysis rather than mediating FFA uptake. We conclude that the VLDLr plays a major role in the metabolism of postprandial lipoproteins by enhancing LPL-mediated TG hydrolysis. Copyright 2004 American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15145981     DOI: 10.1194/jlr.M400009-JLR200

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  29 in total

1.  ApoE and the role of very low density lipoproteins in adipose tissue inflammation.

Authors:  Jiali Wang; Xiaoyuan Dai Perrard; Jerry L Perrard; Aparna Mukherjee; Corina Rosales; Yuguo Chen; C Wayne Smith; Henry J Pownall; Christie M Ballantyne; Huaizhu Wu
Journal:  Atherosclerosis       Date:  2012-06-19       Impact factor: 5.162

2.  Influence of Fatty Acid Modification on Uptake of Lovastatin-Loaded Reconstituted High Density Lipoprotein by Foam Cells.

Authors:  Yun Yang; Ji Wang; Hongliang He; Wenli Zhang; Yuansheng Zhang; Jianping Liu
Journal:  Pharm Res       Date:  2018-05-07       Impact factor: 4.200

3.  Nuclear factor (erythroid-derived 2)-like 2 activation-induced hepatic very-low-density lipoprotein receptor overexpression in response to oxidative stress contributes to alcoholic liver disease in mice.

Authors:  Zhigang Wang; Xiaobing Dou; Songtao Li; Ximei Zhang; Xinguo Sun; Zhanxiang Zhou; Zhenyuan Song
Journal:  Hepatology       Date:  2014-02-25       Impact factor: 17.425

4.  The VLDL receptor promotes lipotoxicity and increases mortality in mice following an acute myocardial infarction.

Authors:  Jeanna C Perman; Pontus Boström; Malin Lindbom; Ulf Lidberg; Marcus StÅhlman; Daniel Hägg; Henrik Lindskog; Margareta Scharin Täng; Elmir Omerovic; Lillemor Mattsson Hultén; Anders Jeppsson; Petur Petursson; Johan Herlitz; Gunilla Olivecrona; Dudley K Strickland; Kim Ekroos; Sven-Olof Olofsson; Jan Borén
Journal:  J Clin Invest       Date:  2011-06-13       Impact factor: 14.808

5.  Increased peripheral lipid clearance in an animal model of amyotrophic lateral sclerosis.

Authors:  Anissa Fergani; Hugues Oudart; Jose-Luis Gonzalez De Aguilar; Bastien Fricker; Frédérique René; Jean-François Hocquette; Vincent Meininger; Luc Dupuis; Jean-Philippe Loeffler
Journal:  J Lipid Res       Date:  2007-04-16       Impact factor: 5.922

6.  Very low density lipoprotein receptor (VLDLR) expression is a determinant factor in adipose tissue inflammation and adipocyte-macrophage interaction.

Authors:  Andrew Nguyen; Huan Tao; Michael Metrione; Tahar Hajri
Journal:  J Biol Chem       Date:  2013-11-29       Impact factor: 5.157

7.  Peroxisome proliferator-activated receptor gamma agonist rosiglitazone increases expression of very low density lipoprotein receptor gene in adipocytes.

Authors:  Takeshi Takazawa; Toshimasa Yamauchi; Atsushi Tsuchida; Makoto Takata; Yusuke Hada; Masato Iwabu; Miki Okada-Iwabu; Kohjiro Ueki; Takashi Kadowaki
Journal:  J Biol Chem       Date:  2009-08-25       Impact factor: 5.157

8.  Peroxisome proliferator-activated receptor-gamma regulates the expression and function of very-low-density lipoprotein receptor.

Authors:  Huan Tao; Srikanth Aakula; Naji N Abumrad; Tahar Hajri
Journal:  Am J Physiol Endocrinol Metab       Date:  2009-10-27       Impact factor: 4.310

Review 9.  Fatty acids as therapeutic auxiliaries for oral and parenteral formulations.

Authors:  Michael J Hackett; Jennica L Zaro; Wei-Chiang Shen; Patrick C Guley; Moo J Cho
Journal:  Adv Drug Deliv Rev       Date:  2012-08-17       Impact factor: 15.470

10.  Peroxisome proliferator-activated receptor-alpha selective ligand reduces adiposity, improves insulin sensitivity and inhibits atherosclerosis in LDL receptor-deficient mice.

Authors:  Rai Ajit K Srivastava; Ravi Jahagirdar; Salman Azhar; Somesh Sharma; Charles L Bisgaier
Journal:  Mol Cell Biochem       Date:  2006-02-14       Impact factor: 3.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.